



## Clinical trial results: An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated with the Investigational PI3K Inhibitor, GS-9820 Summary

EudraCT number	2015-005766-39
Trial protocol	NL
Global end of trial date	28 December 2017

### Results information

Result version number	v2 (current)
This version publication date	31 January 2019
First version publication date	02 January 2019
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li><li>Updating that the study was terminated and removing Race/Ethnicity as data was not collected.</li></ul>

### Trial information

#### Trial identification

Sponsor protocol code	GS-US-313-2120
-----------------------	----------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02739360
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Gilead Sciences
Sponsor organisation address	333 Lakeside Drive, Foster City, CA, United States, 94404
Public contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
Scientific contact	Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	28 December 2017
Is this the analysis of the primary completion data?	Yes
Primary completion date	28 December 2017
Global end of trial reached?	Yes
Global end of trial date	28 December 2017
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study is to provide idelalisib to participants receiving GS-9820 in study GS-US-315-0102 at the time of study closure.

Protection of trial subjects:

The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements. This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	04 May 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 3
Worldwide total number of subjects	3
EEA total number of subjects	3

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0

From 65 to 84 years	3
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants were enrolled at study sites in the Netherlands. The first participant was screened on 04 May 2016. The last study visit occurred on 28 December 2017.

### Pre-assignment

Screening details:

Six participants previously enrolled in Study GS-US-315-0102 were offered screening for enrollment into this study.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	Idelalisib
-----------	------------

Arm description:

Idelalisib administered orally twice daily.

Arm type	Experimental
Investigational medicinal product name	Idelalisib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Idelalisib 150 mg tablet administered orally twice daily.

Number of subjects in period 1	Idelalisib
Started	3
Completed	0
Not completed	3
Study terminated by Sponsor	2
Adverse Event	1

## Baseline characteristics

### Reporting groups

Reporting group title	Idelalisib
-----------------------	------------

Reporting group description:

Idelalisib administered orally twice daily.

Reporting group values	Idelalisib	Total	
Number of subjects	3	3	
Age categorical			
Units: Subjects			
From 65-84 years	3	3	
Gender categorical			
Units: Subjects			
Female	2	2	
Male	1	1	

## End points

### End points reporting groups

Reporting group title	Idelalisib
Reporting group description: Idelalisib administered orally twice daily.	

### Primary: Number of Participants Experiencing Treatment-Emergent $\geq$ Grade 3 Adverse Events, Serious Adverse Events (SAEs), and Deaths

End point title	Number of Participants Experiencing Treatment-Emergent $\geq$ Grade 3 Adverse Events, Serious Adverse Events (SAEs), and Deaths <sup>[1]</sup>
-----------------	--

End point description:

The severity of Adverse Events were graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03. An SAE was defined as an event that, at any dose, resulted in one or more of the following: 1) Death, 2) Life-threatening, 3) In-patient hospitalization or prolongation of existing hospitalization, 4) Persistent or significant disability/incapacity, 5) A congenital anomaly/birth defect, or 6) A medically important event or reaction. Safety Analysis Set included participants who took at least 1 dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

Up to Day 602 plus 30 days

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical comparison was planned or performed.

End point values	Idelalisib			
Subject group type	Reporting group			
Number of subjects analysed	3			
Units: Participants				
$\geq$ Grade 3 Adverse Event	1			
SAE	1			
Death	0			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to Day 602 plus 30 days

Adverse event reporting additional description:

Safety Analysis Set included participants who took at least 1 dose of study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.1
--------------------	------

### Reporting groups

Reporting group title	Idelalisib
-----------------------	------------

Reporting group description:

Idelalisib 150 mg tablet administered orally twice daily.

Serious adverse events	Idelalisib		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 3 (33.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Hepatobiliary disorders			
Cholangitis			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Lung disorder			
alternative assessment type: Non-systematic			
subjects affected / exposed	1 / 3 (33.33%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Idelalisib		
Total subjects affected by non-serious adverse events subjects affected / exposed	3 / 3 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Basal cell carcinoma alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 3 (33.33%)  1		
Vascular disorders Intermittent claudication alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 3 (33.33%)  1		
General disorders and administration site conditions Fatigue alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Influenza like illness alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Oedema peripheral alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Pyrexia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1  1 / 3 (33.33%) 1  1 / 3 (33.33%) 1  1 / 3 (33.33%) 3		
Respiratory, thoracic and mediastinal disorders Bronchitis chronic alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 3 (33.33%)  1		



Psychiatric disorders Delirium alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1		
Investigations Aspartate aminotransferase increased alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1		
Nervous system disorders Dizziness alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Neuralgia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1  1 / 3 (33.33%) 1		
Blood and lymphatic system disorders Anaemia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1		
Eye disorders Vision blurred alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)	1 / 3 (33.33%) 1		
Gastrointestinal disorders Abdominal distension alternative assessment type: Non-systematic subjects affected / exposed occurrences (all)  Constipation alternative assessment type: Non-systematic	1 / 3 (33.33%) 1		

<p>subjects affected / exposed</p> <p>1 / 3 (33.33%)</p> <p>occurrences (all)</p> <p>1</p> <p>Diarrhoea</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 3 (33.33%)</p> <p>occurrences (all)</p> <p>1</p> <p>Dry mouth</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 3 (33.33%)</p> <p>occurrences (all)</p> <p>1</p> <p>Nausea</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 3 (33.33%)</p> <p>occurrences (all)</p> <p>1</p>			
<p>Skin and subcutaneous tissue disorders</p> <p>Skin ulcer</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 3 (33.33%)</p> <p>occurrences (all)</p> <p>1</p>			
<p>Renal and urinary disorders</p> <p>Renal impairment</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 3 (33.33%)</p> <p>occurrences (all)</p> <p>1</p>			
<p>Musculoskeletal and connective tissue disorders</p> <p>Arthralgia</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 3 (33.33%)</p> <p>occurrences (all)</p> <p>2</p>			
<p>Infections and infestations</p> <p>Urinary tract infection</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>3 / 3 (100.00%)</p> <p>occurrences (all)</p> <p>5</p>			



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
28 March 2016	Updates to the safety information and guidelines for toxicity management to be consistent across idelalisib study protocols. These changes include mandated prophylaxis for PJP, CMV surveillance and increased monitoring.
26 August 2016	Dose modification updates, PJP prophylaxis update.
04 November 2016	Revised language around idelalisib administration in the event of pneumonitis.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported